



International Journal of Pharmaceutics and Drug Analysis

Content Available at www.ijpda.org

ISSN: 2348:8948



NANORADIOPHARMACEUTICALS AND RADIATION-BASED NANO SYSTEMS FOR IMAGING AND THERAPEUTIC APPLICATIONS

Are Pradeepthi

Assistant Professor, Department of Pharmaceutics, St. Ann's College of Pharmacy, Chirala.

Received: 21 Dec 2024 Revised: 11 Jan 2025 Accepted: 28 Feb 2025

Abstract

Nano-radiopharmaceuticals and radiation-based nanosystems represent an innovative frontier in the field of medical imaging and therapy. These advanced technologies harness the unique properties of nanomaterials and radioactive isotopes to provide highly targeted diagnostic and therapeutic solutions. Nano-radiopharmaceuticals combine the precision of nanotechnology with the effectiveness of radiation to improve the delivery of radioactive agents to specific sites within the body, enhancing imaging contrast and therapeutic outcomes. These systems can be used for molecular imaging techniques such as positron emission tomography (PET) and single-photon emission computed tomography (SPECT), offering high-resolution, real-time imaging of cellular and tissue-level processes. In therapy, radiation-based nanosystems, such as radiolabeled nanoparticles, are designed to selectively irradiate cancerous cells, reducing damage to surrounding healthy tissues. Furthermore, these nanostructures enable the controlled release of radiation doses, improving treatment efficacy while minimizing side effects. The development of multifunctional nanosystems that integrate diagnostic imaging with therapeutic actions holds great promise for personalized medicine, paving the way for more effective and precise treatments in oncology, neurology, and other fields. However, biocompatibility, stability, and safety must be addressed to translate these technologies into clinical practice. Future research aims to optimize the design of nano-radiopharmaceuticals and radiation-based nanosystems to maximize their therapeutic potential while ensuring minimal toxicity.

Keywords: Nano-radiopharmaceuticals, Radiation-based nanosystems, Medical imaging, Targeted therapy, Molecular imaging, Personalized medicine.

This article is licensed under a Creative Commons Attribution-Non-commercial 4.0 International License. Copyright © 2025 Author(s) retains the copyright of this article.



*Corresponding Author

Are.Pradeepthi

DOI: <https://doi.org/10.47957/ijpda.v13i1.619>

Produced and Published by

[South Asian Academic Publications](#)

Introduction [1, 2]

Nano-radiopharmaceuticals and radiation-based nanosystems have emerged as cutting-edge tools in the fields of medical imaging and therapeutic interventions, revolutionizing the approach to disease diagnosis and treatment. These advanced systems leverage the unique properties of nanomaterials, such as their high surface area, tunable physicochemical characteristics, and the ability to be functionalized with targeting ligands, to enhance the delivery and effectiveness of radioactive agents. By combining nanotechnology with radiopharmaceuticals, these systems provide a powerful platform for precise imaging and targeted therapy.

In medical imaging, nano-radiopharmaceuticals enhance the sensitivity and specificity of diagnostic techniques like positron emission tomography (PET) and single-photon emission computed tomography (SPECT). The nanoscale delivery vehicles improve biodistribution and accumulation at target sites, enabling high-contrast imaging at the molecular and cellular levels. This facilitates the early detection of diseases, including cancer and neurological disorders, by visualizing biomarkers and physiological changes with high resolution and accuracy. Therapeutically, radiation-based nanosystems offer a novel approach to targeted radiotherapy. These nanosystems are designed to selectively deliver therapeutic radiation doses to malignant cells while sparing surrounding healthy tissues. This targeted delivery not only enhances the efficacy of radiotherapy but also minimizes adverse side effects. Furthermore, multifunctional nanosystems that combine diagnostic and therapeutic capabilities-known as theranostics-enable real-time monitoring of treatment efficacy and personalized therapeutic interventions.

Despite their promising potential, several challenges must be addressed before these technologies can be fully integrated into clinical practice. Issues related to biocompatibility, stability, clearance from the body, and potential toxicity need thorough investigation. Moreover, regulatory approvals and large-scale manufacturing pose significant hurdles.

This paper explores the latest advancements in nano-radiopharmaceuticals and radiation-based nanosystems, highlighting their applications in imaging and therapy. It also discusses current challenges and future perspectives, emphasizing the potential of these technologies to transform personalized medicine and improve patient outcomes.

Nanotechnology

Nanotechnology involves research regarding nanoparticles and technology development at the nanoscale, i.e., at the atomic, molecular, or macromolecular level. The field aims to create devices, structures, and systems that have useful properties and functions. Alongside this, it also provides a better understanding of materials and phenomena at the nanoscale. The use of nanotechnology has provided solutions to many medical problems, including smart nanomaterials for targeted drug delivery, bringing disruptive innovation to the field of oncology.

Radiation Therapy

Radiation therapy (RT) involves the utilization of high doses of electromagnetic radiation to destroy tumors or cancerous cells in the body. After the discovery and clinical exploitation of X-rays in cancer treatment, radiation therapy developed into a recognized medical specialty. Radiation therapy is becoming particularly important in cancer treatment, along with chemotherapeutic and surgery approaches, as it is very cost-effective, accounting for only 5% of the total cancer care cost. About 50% of all patients suffering from cancer undergo radiation therapy during their course of treatment, and it is estimated that radiation therapy can contribute to around 40% of curative treatment. The radiation used during therapy can kill the cancerous cells directly or destroy the ability of cancerous cells to proliferate further by damaging their genetic material. Radiation therapy has been established as an important clinical modality for the treatment of several malignancies, such as lung carcinoma, gynecological cancers, thyroid carcinomas, central nervous system neoplasms, hematologic malignancies, breast carcinoma, melanoma, prostate tumors, gastrointestinal cancers, and cervix tumors. Even though radiation therapy is widely used around the world for the treatment of cancer, it does possess many side effects as well. Several radiation treatments are currently being used or developed for the treatment of cancer, including External beam radiotherapy (EBRT), Intensity-modulated radiotherapy (IMRT), Image-guided radiotherapy (IGRT), Cone beam

computer tomography (CBCT), Stereotactic body radiotherapy (SBRT), Stereotactic radiosurgery (SRS), High-dose radiation (HDR) and Low-dose radiation (LDR), etc. as documented in Fig. 1. EBRT involves all the clinical modalities that are based on radiation therapy using linear accelerators to provide safe and efficacious treatment against cancer. IMRT is a radiotherapy treatment that, to decrease the exposure of radiation to other tissues, involves conforming the shape of the radiation distribution to mimic the shape and size of the tumor. IGRT is a radiation therapy with improved and highly targeted delivery of radiation. In the past, tumors were irradiated using two-dimensional (2D) imaging without considering the protection of the normal tissues. As a result, even slight deviations or positional errors used to cause unwanted damage to healthy tissues. IGRT, in contrast, can detect such errors by acquiring information through pre-radiotherapy imaging, which allows for correction before the treatment begins. SBRT is another relatively new approach that can be used to get rid of small, well-defined cancer tumors. It offers hypofractionated dose regimens, which are given in less than five fractions, which in turn improves local control and survival.




Fig. 1. Currently being used radiation therapies for cancer treatment.

Nanotechnology-based radiotherapy

Nanotechnology has been widely used in cancer therapy and diagnosis. Although much of the research in nanotechnology for oncology is focused on diagnostics and chemotherapy delivery, research is also being carried out on applying nanotechnology to improve radiation oncology. Although widely used, clinical radiotherapy still often fails to attain the desired outcomes regarding cancer treatment because of many constraining factors. Nanotechnology, as an emerging multi-disciplinary field of science and technology, has become a promising research direction in cancer treatment. Nanomaterials, because of their extraordinary physical as well as chemical properties, have been used to enhance the effectiveness of radiation therapy and to overcome the tolerance of cancerous cells towards radiation.

Nanoparticles For Enhanced radiotherapy [3]

Nanoparticles (NPs) have emerged as powerful tools for enhancing radiotherapy due to their unique physicochemical properties. They improve the therapeutic efficacy of radiation by increasing tumor

radiosensitivity while minimizing damage to surrounding healthy tissues. Here's a summary of how they work and their benefits:

Mechanisms of Action

- Radio-sensitization:** High atomic number (Z) nanoparticles, such as gold (AuNPs) and platinum (PtNPs), enhance the local radiation dose by generating secondary electrons when exposed to ionizing radiation, leading to increased DNA damage in cancer cells.
- Reactive Oxygen Species (ROS) Generation:** Some NPs produce ROS upon radiation, amplifying oxidative stress and damaging cellular components, especially DNA.
- Tumor Targeting and Penetration:** NPs can be engineered for enhanced permeability and retention (EPR) effect, allowing them to accumulate more efficiently in tumor tissues.
- Drug Delivery:** NPs can be loaded with chemotherapeutic agents or radiosensitizers, facilitating a synergistic effect between radiotherapy and chemotherapy.

Types of Nanoparticles Used

- Metallic Nanoparticles:** Gold, platinum, and bismuth NPs are popular for their high Z values and efficient radiation dose enhancement.
- Semiconductor Nanoparticles:** Quantum dots and titanium dioxide NPs are known for ROS generation.
- Polymeric and Lipid-Based NPs:** These are used for targeted drug delivery and controlled release in combination therapies.

Advantages

- Enhanced Tumor Radiosensitivity:** Increases effectiveness of lower radiation doses.
- Reduced Side Effects:** By minimizing radiation exposure to surrounding healthy tissues.
- Multifunctionality:** Combining imaging, targeting, and therapy in one platform.
- Customizable Surface Modifications:** Enhances biocompatibility and targeted delivery.




Figure 2. Mechanism of radiosensitization and strategies synergistic with RT

Imaging and Therapeutic Nano radiopharmaceuticals and Radiation-Based Nanosystems [4]

Imaging and Therapeutic nano radiopharmaceuticals and Radiation-Based Nanosystems are cutting-edge technologies combining nanotechnology with radiopharmaceuticals to enhance both diagnostic imaging and therapeutic radiotherapy.

1. Imaging Nano-radiopharmaceuticals

These nanoparticles (NPs) are designed for enhanced diagnostic imaging, offering high sensitivity, resolution, and target specificity. They improve the visualization of tumors and other pathological conditions.

Types and Applications

Positron Emission Tomography (PET) and Single Photon Emission Computed Tomography (SPECT):

- Radioisotopes Used:**
 - PET:** ^{18}F , ^{64}Cu , ^{68}Ga
 - SPECT:** $^{99\text{m}}\text{Tc}$, ^{111}In
- Nanoparticle Platforms:** Gold NPs, Quantum Dots, Liposomes, and Silica NPs.
- Applications:** Tumor imaging, inflammation detection, and monitoring drug delivery.
- Magnetic Resonance Imaging (MRI):**
 - Contrast Agents:** Superparamagnetic iron oxide nanoparticles (SPIONs) and gadolinium-based NPs.
 - Benefits:** High spatial resolution and tissue contrast for detailed anatomical imaging.
- Computed Tomography (CT)**
 - Nanomaterials:** Gold NPs due to high atomic number and X-ray absorption capacity.
 - Applications:** Vascular imaging, tumor margin delineation, and detecting microcalcifications.

2. Therapeutic Nanoradiopharmaceuticals

These systems deliver therapeutic radioisotopes directly to cancer cells, minimizing damage to healthy tissues. They offer high precision in radiotherapy, especially for metastatic and hard-to-treat tumors.

Types and Mechanisms:

Alpha-Emitters

Isotopes Used: ^{225}Ac , ^{213}Bi

Advantages: High linear energy transfer (LET) leading to localized and highly potent cytotoxicity.

Applications: Targeted alpha therapy (TAT) for metastatic cancer treatment.

Beta-Emitters

Isotopes Used: ^{177}Lu , ^{131}I

Mechanism: Induces DNA damage through beta particle emission.

Applications: Treatment of neuroendocrine tumors and thyroid cancers.

Auger Electron Emitters

Isotopes Used: ^{111}In , ^{125}I

Mechanism: Short-range emissions leading to localized DNA damage.

Applications: Precision targeting for intracellular therapeutic effects.

3. Radiation-Based Nanosystems

These are hybrid nanosystems designed to enhance the effectiveness of traditional radiation therapy. They work by increasing radiation dose deposition or acting as radiosensitizers.

Mechanisms and Components

Radiosensitization

High-Z Nanoparticles: Gold (AuNPs), Hafnium oxide (HfO₂) NPs.

Mechanism: Enhance radiation dose deposition via secondary electron emission.

Applications: Boost efficacy of external beam radiotherapy (EBRT).

Reactive Oxygen Species (ROS) Generation

Nanoparticles Used: Titanium dioxide (TiO₂), Cerium oxide (CeO₂).

Mechanism: Photocatalytic ROS generation under radiation, enhancing oxidative stress in cancer cells.

Combined Therapy Platforms

Multifunctional NPs: Combining imaging, drug delivery, and radiotherapy in one platform.

Examples: Liposomes loaded with radiosensitizers and imaging agents for theranostics.

4. Challenges and Future Directions:

Biocompatibility and Safety: Long-term toxicity, biodistribution, and clearance need thorough investigation.

Targeting Efficiency: Improving selectivity for cancer cells to minimize off-target effects.

Clinical Translation: Regulatory challenges and the need for large-scale clinical trials.

Personalized Medicine: Development of patient-specific nanoradiopharmaceuticals for precision oncology.

5. Recent Advances and Research Trends:

Multimodal Imaging Probes: NPs combining PET/MRI or SPECT/CT for comprehensive diagnostic data.

Smart Nanosystems: Stimuli-responsive NPs for controlled drug release triggered by radiation.

Immuno-Nanoradiopharmaceuticals: Combining immunotherapy with radiopharmaceuticals for enhanced anti-tumor immunity. These advancements are paving the way for next-generation cancer diagnostics and therapy, emphasizing personalized and precision medicine.

Future Prospects of Nanoradiopharmaceuticals and Radiation-Based Nanosystems for Imaging and Therapeutics [5]

Nanoradiopharmaceuticals and radiation-based nanosystems are revolutionizing the fields of medical imaging and cancer therapy. Their prospects are highly promising, driven by continuous advancements in

nanotechnology, radiochemistry, and personalized medicine. Here are the key areas of development and emerging trends:

1. Personalized and Precision Medicine

Patient-Specific Radiopharmaceuticals: Development of tailored nanoradiopharmaceuticals based on patient-specific tumor markers and genetic profiles to enhance targeting accuracy.

Theranostics: Integrating diagnostics and therapy in a single nanoparticle platform for real-time monitoring of therapeutic response and dose optimization.

Artificial Intelligence Integration: Utilizing AI for personalized treatment planning, image analysis, and predicting therapeutic outcomes.

2. Advanced Imaging Techniques

Multimodal Imaging Probes: Development of nanoparticles combining multiple imaging modalities (e.g., PET/MRI, SPECT/CT) for comprehensive anatomical, functional, and molecular imaging.

Higher Resolution and Sensitivity: Innovations in nanoparticle design to improve imaging resolution, sensitivity, and specificity for early disease detection.

Non-Invasive Imaging Agents: Creation of biocompatible and non-toxic nanosystems for safer and more effective diagnostic procedures.

3. Enhanced Targeting and Delivery Mechanisms

Active Targeting Strategies: Use of ligands, antibodies, and aptamers to enhance the specificity of nanoparticle targeting to cancer cells.

Stimuli-Responsive Systems: Smart nanoparticles that release therapeutic agents in response to specific stimuli like pH, temperature, or radiation.

Blood-Brain Barrier Penetration: Development of NPs capable of crossing the blood-brain barrier for imaging and treating brain tumors and neurological disorders.

4. Novel Therapeutic Approaches

Combination Therapies: Integrating nanoradiopharmaceuticals with immunotherapy, chemotherapy, and gene therapy for synergistic therapeutic effects.

Targeted Alpha Therapy (TAT): Utilization of alpha-emitting isotopes like ^{225}Ac and ^{213}Bi for highly potent and localized cytotoxicity in metastatic cancers.

Auger Electron Therapy: Advanced delivery of Auger electron emitters for intracellular DNA damage with minimal systemic toxicity.

5. Safety, Biocompatibility, and Regulatory Challenges

Biodegradable and Biocompatible NPs: Development of biodegradable nanoparticle formulations to minimize toxicity and enhance clearance from the body.

Long-Term Safety Studies: Conducting comprehensive preclinical and clinical trials to assess long-term safety and biodistribution.

Regulatory Approvals: Streamlining regulatory pathways and standardizing manufacturing protocols for clinical translation.

6. Emerging Materials and Design Innovations

Hybrid Nanostructures: Combining multiple materials (e.g., gold-silica hybrids) for enhanced imaging contrast and therapeutic efficacy.

Self-Assembling Nanoparticles: Designing self-assembling nanosystems for better control over size, shape, and drug loading capacity.

Quantum Dots and Carbon Nanomaterials: Exploration of quantum dots and carbon-based NPs (e.g., graphene, carbon nanotubes) for advanced imaging and radiotherapy enhancement.

7. Clinical Translation and Commercialization

Scalable Production Techniques: Developing cost-effective and scalable manufacturing processes for commercial viability.

Collaboration and Funding: Increased collaboration between academia, industry, and regulatory agencies to accelerate research and clinical applications.

Market Growth and Adoption: The Growing demand for personalized medicine and non-invasive diagnostic techniques is likely to boost market growth and clinical adoption.

8. Potential Applications beyond Oncology

Neurological Imaging and Therapy: Application in neuroimaging for Alzheimer's and Parkinson's disease and targeted radiotherapy for brain tumors.

Cardiovascular Imaging: Development of nanoparticle-based contrast agents for enhanced imaging of atherosclerotic plaques and myocardial infarctions.

Infectious Disease Detection: Utilization of radiolabeled NPs for detecting bacterial infections and monitoring inflammatory diseases.

Conclusion [6]

Nanoradiopharmaceuticals and radiation-based nanosystems represent a transformative advancement in medical imaging and cancer therapeutics. Their unique physicochemical properties enable enhanced imaging sensitivity, high targeting specificity, and effective dose delivery, significantly improving diagnostic accuracy and therapeutic outcomes. By integrating diagnosis and therapy (theranostics), these nanosystems provide a personalized approach to cancer treatment, minimizing damage to healthy tissues and maximizing therapeutic efficacy.

Despite the remarkable progress, challenges such as biocompatibility, long-term safety, and regulatory hurdles remain. Continued research is essential to optimize nanoparticle design, enhance targeting efficiency, and ensure safe clinical translation. With rapid technological advancements and growing interest in precision medicine, nano-radiopharmaceuticals and radiation-based nanosystems are poised to revolutionize the future of oncology, offering more effective, safer, and personalized treatment modalities.

Funding

Nil

Acknowledgement

Not Declared.

Conflict of Interest

No Conflict of interest

Informed Consent and Ethical Statement

Not Applicable.

References

1. Jain, S., Hirst, D. G., & O'Sullivan, J. M. (2012). "Gold nanoparticles as novel agents for cancer therapy." *The British Journal of Radiology*, 85(1010), 101-113. [doi:10.1259/bjr/59448833](https://doi.org/10.1259/bjr/59448833)
2. Song, G., Cheng, L., Chao, Y., & Yang, K. (2017). "Emerging nanotechnology and advanced materials for cancer radiation therapy." *Advanced Materials*, 29(32), 1700996. [doi:10.1002/adma.201700996](https://doi.org/10.1002/adma.201700996)
3. Chakravarty, R., Goel, S., & Cai, W. (2014). "Nanobody: the 'magic bullet' for molecular imaging?" *Theranostics*, 4(4), 386-398. [doi:10.7150/thno.8006](https://doi.org/10.7150/thno.8006)
4. Her, S., Jaffray, D. A., & Allen, C. (2017). "Gold nanoparticles for applications in cancer radiotherapy: Mechanisms and recent advancements." *Advanced Drug Delivery Reviews*, 109, 84-101. [doi:10.1016/j.addr.2016.11.006](https://doi.org/10.1016/j.addr.2016.11.006)
5. Schuemann, J., Berbeco, R., Chattopadhyay, N., & Kumar, R. (2020). "Nanoparticles for cancer treatment: precision radiotherapy with new horizons." *Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology*, 12(1), e1576. [doi:10.1002/wnan.1576](https://doi.org/10.1002/wnan.1576)
6. Prasad, R. Y., Wallace, K., Daniel, S., & Tennant, A. H. (2013). "Nanoparticles as radiation sensitizers: A review of experimental and clinical studies." *Journal of Nanoscience and Nanotechnology*, 13(1), 1-13. [doi:10.1166/jnn.2013.6896](https://doi.org/10.1166/jnn.2013.6896)
7. Chen, W., Zhang, S., Yu, Y., & Zhang, H. (2019). "Nanotechnology in radiotherapy for gastrointestinal cancers." *Nanomedicine: Nanotechnology, Biology, and Medicine*, 20, 102030. [doi:10.1016/j.nano.2019.102030](https://doi.org/10.1016/j.nano.2019.102030)
8. Dadachova, E., & Mirzadeh, S. (2020). "Nanotechnology in targeted radionuclide therapy." *Molecular Imaging and Biology*, 22, 421-429. [doi:10.1007/s11307-019-01391-w](https://doi.org/10.1007/s11307-019-01391-w)
9. Rosenkranz, A. A., Slastnikova, T. A., Durymanov, M. O., & Sobolev, A. S. (2014). "Targeted intracellular delivery of radiopharmaceuticals for cancer treatment." *Biochimica et Biophysica Acta (BBA) - Reviews on Cancer*, 1846(1), 239-257. [doi:10.1016/j.bbcan.2014.07.002](https://doi.org/10.1016/j.bbcan.2014.07.002)
10. Thakor, A. S., & Gambhir, S. S. (2013). "Nanooncology: The future of cancer diagnosis and therapy." *CA: A Cancer Journal for Clinicians*, 63(6), 395-418. [doi:10.3322/caac.21199](https://doi.org/10.3322/caac.21199)
11. Jiang, Y., Huo, S., Mizuhara, T., Das, R., & Rotello, V. M. (2015). "Nanotechnology in radiation therapy: From

- bench to bedside." *Bioconjugate Chemistry*, 26(6), 1142-1153. [doi:10.1021/acs.bioconjchem.5b00119](https://doi.org/10.1021/acs.bioconjchem.5b00119)
12. Barreto, J. A., O'Malley, W., Kubeil, M., Graham, B., Stephan, H., & Spiccia, L. (2011). "Nanomaterials: Applications in cancer imaging and therapy." *Advanced Materials*, 23(12), H18-H40. [doi:10.1002/adma.201004496](https://doi.org/10.1002/adma.201004496)
 13. Akhtar, N., Akram, M., Daniyal, M., & Ahmad, S. (2018). Evaluation of antidiabetic activity of Ipomoea batatas L. extract in alloxan-induced diabetic rats. *International Journal of Immunopathology and Pharmacology*, 32, 205873841881467. <https://doi.org/10.1177/2058738418814678>
 14. Ranjith, D., & Viswanath, S. (2019). In silico antidiabetic activity of bioactive compounds in Ipomoea mauritiana Jacq [Journal-article]. *The Pharma Innovation Journal*, 8-10, 05-11.
 15. Rauniyar, N., & Srivastava, D. (2020). Ipomoea digitata: A therapeutic boon from nature to mankind. *The Journal of Indian Botanical Society*, 100(3and4), 185-191. <https://doi.org/10.5958/2455-7218.2020.00039.x>